| Grant number: | 12/10739-0 |
| Support Opportunities: | Regular Research Grants |
| Start date: | September 01, 2012 |
| End date: | August 31, 2014 |
| Field of knowledge: | Health Sciences - Medicine - Medical Clinics |
| Principal Investigator: | Antonio Augusto Barbosa Lopes |
| Grantee: | Antonio Augusto Barbosa Lopes |
| Host Institution: | Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil |
| City of the host institution: | São Paulo |
Abstract
Sildenafil (20 mg t.i.d.) and tadalafil (40 mg, single daily dose) are oral therapies approved for pulmonary arterial hypertension (PAH). Because there are no comparative studies using these drugs, the present study is aimed at comparing their effects in subjects with PAH associated with congenital heart disease (so called Eisenmenger syndrome). The study will be randomized, and performed over six months. The impact of treatments on the physical capacity will be tested by the six-minute walk test, and pulse oxymetry. Health-related quality of life will be analyzed as well. The possible impact of both phosphodiesterase-5 inhibitors on endothelial and platelet dysfunction will be analyzed by measuring the circulating levels of von Willebrand fact, tissue-type plasminogen activator, Thrombomodulin, P-selectin, beta-thromboglobulin and soluble CD40-L. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |